

Lloyd T Lam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6344542/publications.pdf>

Version: 2024-02-01

14
papers

3,739
citations

759233

12
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

7299
citing authors

#	ARTICLE	IF	CITATIONS
1	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nature Medicine</i> , 2013, 19, 202-208.	30.7	2,426
2	Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. <i>Nature</i> , 2017, 550, 128-132.	27.8	498
3	Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. <i>Nature</i> , 2020, 578, 306-310.	27.8	259
4	Potential mechanisms of resistance to venetoclax and strategies to circumvent it. <i>BMC Cancer</i> , 2017, 17, 399.	2.6	141
5	Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies. <i>Cancer Research</i> , 2017, 77, 2976-2989.	0.9	100
6	Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1511-1520.	4.1	61
7	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	61
8	A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax). <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2943-2950.	4.1	52
9	Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2543-2550.	4.1	52
10	Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer. <i>Molecular Cancer</i> , 2015, 14, 126.	19.2	42
11	Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1809-1819.	4.1	17
12	Biomarkers of Therapeutic Response to BCL2 Antagonists in Cancer. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 347-356.	3.8	13
13	Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines. <i>Cancer Cell International</i> , 2015, 15, 5.	4.1	12
14	Multiplex Analysis of Anti-Apoptotic BCL2 Family and Caspase 3 Activation by Microbead Arrays. <i>Assay and Drug Development Technologies</i> , 2014, 12, 190-196.	1.2	5